Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials.
Noepel-Duennebacke S, Juette H, Schulmann K, Graeven U, Porschen R, Stoehlmacher J, Hegewisch-Becker S, Raulf A, Arnold D, Reinacher-Schick A, Tannapfel A. Noepel-Duennebacke S, et al. Among authors: schulmann k. J Cancer Res Clin Oncol. 2021 Oct;147(10):3063-3072. doi: 10.1007/s00432-021-03559-w. Epub 2021 Mar 6. J Cancer Res Clin Oncol. 2021. PMID: 33675399 Free PMC article.
Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.
Baraniskin A, Munding J, Schulmann K, Meier D, Porschen R, Arkenau HT, Graeven U, Schmiegel W, Tannapfel A, Reinacher-Schick A. Baraniskin A, et al. Among authors: schulmann k. Clin Colorectal Cancer. 2011 Mar 1;10(1):24-9. doi: 10.3816/CCC.2011.n.003. Clin Colorectal Cancer. 2011. PMID: 21609932
Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group.
Reinacher-Schick A, Schulmann K, Modest DP, Bruns N, Graeven U, Jaworska M, Greil R, Porschen R, Arnold D, Schmiegel W, Tannapfel A. Reinacher-Schick A, et al. Among authors: schulmann k. BMC Cancer. 2012 Aug 9;12:349. doi: 10.1186/1471-2407-12-349. BMC Cancer. 2012. PMID: 22876876 Free PMC article. Clinical Trial.
Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy.
Nöpel-Dünnebacke S, Schulmann K, Reinacher-Schick A, Porschen R, Schmiegel W, Tannapfel A, Graeven U. Nöpel-Dünnebacke S, et al. Among authors: schulmann k. Z Gastroenterol. 2014 Dec;52(12):1394-401. doi: 10.1055/s-0034-1366781. Epub 2014 Dec 4. Z Gastroenterol. 2014. PMID: 25474278 Clinical Trial.
Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group.
Müller CI, Schulmann K, Reinacher-Schick A, Andre N, Arnold D, Tannapfel A, Arkenau H, Hahn SA, Schmoll SH, Porschen R, Schmiegel W, Graeven U; AIO Colorectal Study Group. Müller CI, et al. Among authors: schulmann k. Int J Colorectal Dis. 2008 Nov;23(11):1033-9. doi: 10.1007/s00384-008-0504-2. Epub 2008 Jul 2. Int J Colorectal Dis. 2008. PMID: 18594845 Clinical Trial.
[S3-guideline colorectal cancer version 1.0].
Pox C, Aretz S, Bischoff SC, Graeven U, Hass M, Heußner P, Hohenberger W, Holstege A, Hübner J, Kolligs F, Kreis M, Lux P, Ockenga J, Porschen R, Post S, Rahner N, Reinacher-Schick A, Riemann JF, Sauer R, Sieg A, Scheppach W, Schmitt W, Schmoll HJ, Schulmann K, Tannapfel A, Schmiegel W; Leitlinienprogramm Onkologie der AWMF; Deutschen Krebsgesellschaft e. V; Deutschen Krebshilfe e. V. Pox C, et al. Among authors: schulmann k. Z Gastroenterol. 2013 Aug;51(8):753-854. doi: 10.1055/s-0033-1350264. Epub 2013 Aug 16. Z Gastroenterol. 2013. PMID: 23955142 Free article. German. No abstract available.
TFAP2E-DKK4 and chemoresistance in colorectal cancer.
Ebert MP, Tänzer M, Balluff B, Burgermeister E, Kretzschmar AK, Hughes DJ, Tetzner R, Lofton-Day C, Rosenberg R, Reinacher-Schick AC, Schulmann K, Tannapfel A, Hofheinz R, Röcken C, Keller G, Langer R, Specht K, Porschen R, Stöhlmacher-Williams J, Schuster T, Ströbel P, Schmid RM. Ebert MP, et al. Among authors: schulmann k. N Engl J Med. 2012 Jan 5;366(1):44-53. doi: 10.1056/NEJMoa1009473. N Engl J Med. 2012. PMID: 22216841 Free article.
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Al-Batran SE, et al. Among authors: schulmann k. Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11. Lancet. 2019. PMID: 30982686 Clinical Trial.
67 results